CYP2D6 and breast carcinoma: An analysis of 20 breast cancer cohorts using tamoxifen indicated that rescoring the CYP2D6*10 allele to an activity of 0.25 increased the prediction of endoxifen in Asian cohorts and to a lesser extent in Caucasians [91].